Sinopharm
1099.HK
#1856
Rank
$6.93 B
Marketcap
$2.22
Share price
0.23%
Change (1 day)
-5.93%
Change (1 year)
The Sinopharm Group is a Chinese pharmaceutical company that researches, develops, produces, sells and markets pharmaceuticals and other health products.

P/E ratio for Sinopharm (1099.HK)

P/E ratio at the end of 2021: 5.44

According to Sinopharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 5.68115. At the end of 2021 the company had a P/E ratio of 5.44.

P/E ratio history for Sinopharm from 2009 to 2021

PE ratio at the end of each year

Year P/E ratio Change
20215.44-17.02%
20206.56-45.23%
201912.0-13.26%
201813.8-5.85%
201714.7-12.82%
201616.8-10.03%
201518.7-3.44%
201419.40.02%
201319.4-18.75%
201223.85.26%
201122.6-47.83%
201043.4-15.39%
200951.3

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.